415 related articles for article (PubMed ID: 33710393)
1. Modern day screening for Lynch syndrome in endometrial cancer: the KEM experience.
Pauly N; Baert T; Schmutzler R; du Bois A; Schneider S; Rhiem K; Schömig-Markiefka B; Siemanowski J; Heikaus S; Traut A; Heitz F; Prader S; Ehmann S; Harter P; Ataseven B
Arch Gynecol Obstet; 2021 Oct; 304(4):975-984. PubMed ID: 33710393
[TBL] [Abstract][Full Text] [Related]
2. The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study.
Ryan NAJ; McMahon R; Tobi S; Snowsill T; Esquibel S; Wallace AJ; Bunstone S; Bowers N; Mosneag IE; Kitson SJ; O'Flynn H; Ramchander NC; Sivalingam VN; Frayling IM; Bolton J; McVey RJ; Evans DG; Crosbie EJ
PLoS Med; 2020 Sep; 17(9):e1003263. PubMed ID: 32941469
[TBL] [Abstract][Full Text] [Related]
3. Comparison of screening strategies for Lynch syndrome in patients with newly diagnosed endometrial cancer: a prospective cohort study in China.
Chao X; Li L; Wu M; Ma S; Tan X; Zhong S; Bi Y; Lang J
Cancer Commun (Lond); 2019 Jul; 39(1):42. PubMed ID: 31307542
[TBL] [Abstract][Full Text] [Related]
4. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.
Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D
J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419
[TBL] [Abstract][Full Text] [Related]
5. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
[TBL] [Abstract][Full Text] [Related]
6. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
[TBL] [Abstract][Full Text] [Related]
7. Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?
Kahn RM; Gordhandas S; Maddy BP; Baltich Nelson B; Askin G; Christos PJ; Caputo TA; Chapman-Davis E; Holcomb K; Frey MK
Cancer; 2019 Sep; 125(18):3172-3183. PubMed ID: 31150123
[TBL] [Abstract][Full Text] [Related]
8. Lynch Syndrome in Thai Endometrial Cancer Patients.
Manchana T; Ariyasriwatana C; Triratanachat S; Phowthongkum P
Asian Pac J Cancer Prev; 2021 May; 22(5):1477-1483. PubMed ID: 34048176
[TBL] [Abstract][Full Text] [Related]
9. An Analysis of Clinical, Surgical, Pathological and Molecular Characteristics of Endometrial Cancer According to Mismatch Repair Status. A Multidisciplinary Approach.
Dondi G; Coluccelli S; De Leo A; Ferrari S; Gruppioni E; Bovicelli A; Godino L; Coadă CA; Morganti AG; Giordano A; Santini D; Ceccarelli C; Turchetti D; De Iaco P; Perrone AM
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003368
[TBL] [Abstract][Full Text] [Related]
10. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.
Buchanan DD; Tan YY; Walsh MD; Clendenning M; Metcalf AM; Ferguson K; Arnold ST; Thompson BA; Lose FA; Parsons MT; Walters RJ; Pearson SA; Cummings M; Oehler MK; Blomfield PB; Quinn MA; Kirk JA; Stewart CJ; Obermair A; Young JP; Webb PM; Spurdle AB
J Clin Oncol; 2014 Jan; 32(2):90-100. PubMed ID: 24323032
[TBL] [Abstract][Full Text] [Related]
11. Frequent loss of mutation-specific mismatch repair protein expression in nonneoplastic endometrium of Lynch syndrome patients.
Wong S; Hui P; Buza N
Mod Pathol; 2020 Jun; 33(6):1172-1181. PubMed ID: 31932681
[TBL] [Abstract][Full Text] [Related]
12. Universal screening of both endometrial and colon cancers increases the detection of Lynch syndrome.
Adar T; Rodgers LH; Shannon KM; Yoshida M; Ma T; Mattia A; Lauwers GY; Iafrate AJ; Hartford NM; Oliva E; Chung DC
Cancer; 2018 Aug; 124(15):3145-3153. PubMed ID: 29750335
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening.
Carr C; Son J; Yao M; Priyadarshini A; Marquard J; Vargas R; Michener C; AlHilli MM
Gynecol Oncol; 2020 Dec; 159(3):712-720. PubMed ID: 33046272
[TBL] [Abstract][Full Text] [Related]
14. Lynch syndrome-associated endometrial carcinoma with MLH1 germline mutation and MLH1 promoter hypermethylation: a case report and literature review.
Yokoyama T; Takehara K; Sugimoto N; Kaneko K; Fujimoto E; Okazawa-Sakai M; Okame S; Shiroyama Y; Yokoyama T; Teramoto N; Ohsumi S; Saito S; Imai K; Sugano K
BMC Cancer; 2018 May; 18(1):576. PubMed ID: 29783979
[TBL] [Abstract][Full Text] [Related]
15. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
Jin W; Wang LQ; Liu Y; Liu AJ
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
[No Abstract] [Full Text] [Related]
16. Somatic Sequencing and Microsatellite Instability Results From Mismatch Repair-deficient Endometrial Carcinoma Patients Without Lynch Syndrome ("Lynch-like" tumors): Implications for Heritable Cancer Screening, Molecular Prognostication, and Immunotherapeutic Vulnerability.
Makia NL; Thomas M; Ring KL; Moskaluk CA; Mills AM
Am J Surg Pathol; 2023 Aug; 47(8):878-888. PubMed ID: 37248962
[TBL] [Abstract][Full Text] [Related]
17. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.
Dillon JL; Gonzalez JL; DeMars L; Bloch KJ; Tafe LJ
Hum Pathol; 2017 Dec; 70():121-128. PubMed ID: 29107668
[TBL] [Abstract][Full Text] [Related]
18. Isolated Loss of PMS2 Immunohistochemical Expression is Frequently Caused by Heterogenous MLH1 Promoter Hypermethylation in Lynch Syndrome Screening for Endometrial Cancer Patients.
Kato A; Sato N; Sugawara T; Takahashi K; Kito M; Makino K; Sato T; Shimizu D; Shirasawa H; Miura H; Sato W; Kumazawa Y; Sato A; Kumagai J; Terada Y
Am J Surg Pathol; 2016 Jun; 40(6):770-6. PubMed ID: 26848797
[TBL] [Abstract][Full Text] [Related]
19. Clinical and histomolecular endometrial tumor characterization of patients at-risk for Lynch syndrome in South of Brazil.
Cossio SL; Koehler-Santos P; Pessini SA; Mónego H; Edelweiss MI; Meurer L; Errami A; Coffa J; Bock H; Saraiva-Pereira ML; Ashton-Prolla P; Prolla JC
Fam Cancer; 2010 Jun; 9(2):131-9. PubMed ID: 19821155
[TBL] [Abstract][Full Text] [Related]
20. Screening for Lynch syndrome using risk assessment criteria in patients with ovarian cancer.
Takeda T; Tsuji K; Banno K; Yanokura M; Kobayashi Y; Tominaga E; Aoki D
J Gynecol Oncol; 2018 May; 29(3):e29. PubMed ID: 29400022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
